Entry into or termination of material definitive agreements (Items 1.01/1.02).
USBC, Inc. entered into Agreement with Vast Bank, N.A. and Uphold HQ Inc. (effective 2026-01-20).
“On January 20, 2026 (the “Effective Date”), USBC, Inc. (the “Company”) entered into a strategic partnership agreement (the “Agreement”) with Vast Bank, N.A., a national banking association (“Vast Bank”) and Uphold HQ Inc., a South Carolina corporation (“Uphold”).”
Nuo Therapeutics, Inc. entered into Loan and Security Agreement with four lenders (collectively, the "Lenders") valued at up to $1.6 million (effective 2026-01-21).
“On January 21, 2026, Nuo Therapeutics, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Loan Agreement”) with four lenders (collectively, the “Lenders”). The Loan Agreement provides for loans in an aggregate principal amount of up to $1.6 million”
GOLD RESOURCE CORP entered into Arrangement Agreement and Plan of Merger with Goldgroup Mining Inc. and Goldgroup Merger Sub Inc. (effective 2026-01-25).
“On January 25, 2026, Gold Resource Corporation (the “Company”) entered into an Arrangement Agreement and Plan of Merger (the “Arrangement Agreement”) with Goldgroup Mining Inc., a corporation incorporated under the laws of the Province of British Columbia (“Goldgroup”), and Goldgroup Merger Sub Inc., a Colorado corporation and direct subsidiary of Goldgroup (“Purchaser Sub”).”
TD SYNNEX CORP amended Seventh Omnibus Amendment to the Fifth Amended and Restated Receivables Funding and Administration Agreement with The Toronto-Dominion Bank Ltd., as administrative agent (effective 2026-01-21).
“On January 21, 2026, TD SYNNEX Corporation ("TD SYNNEX"), its subsidiaries that are originators thereunder and its subsidiary - SIT Funding LLC (“SIT”) - which is the borrower thereunder, amended TD SYNNEX’s accounts receivable securitization program (the “Trade Receivables Securitization”) by entering into the Seventh Omnibus Amendment to the Fifth Amended and Restated Receivables Funding and Administration Agreement (the “RFA”) and the Third Amended and Restated Receivables Sale and Servicing Agreement (the “SSA”), (the “Amendment”), among TD SYNNEX, SIT, the subsidiary originators, the lenders and managing agents party thereto, and The Toronto-Dominion Bank Ltd., as administrative agent (the “Administrative Agent”).”
OLB GROUP, INC. entered into Placement Agency Agreement with D. Boral Capital LLC (effective 2026-01-22).
“that certain placement agency agreement, dated January 22, 2026 (the “Placement Agency Agreement”), by and between the Company and D. Boral”
OLB GROUP, INC. entered into Purchase Agreement with certain institutional investors valued at aggregate gross proceeds to the Company from the Offering were approximately $1.3 million (effective 2026-01-22).
“On January 22, 2026, The OLB Group, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”)”
ImmunityBio, Inc. amended Convertible Note Amendment with Nant Capital, LLC (effective 2026-01-23).
“On January 23, 2026, ImmunityBio, Inc. (the “Company”) entered into a letter amendment (the “Convertible Note Amendment”) to that certain convertible Second Amended and Restated Promissory Note, dated December 10, 2024, in an outstanding principal amount of $505.0 million (the “Convertible Promissory Note”), by and among the Company and Nant Capital, LLC (the “Holder”), an entity affiliated with Dr. Patrick Soon-Shiong, the Company’s Executive Chairman and Global Chief Scientific and Medical Officer.”
Leidos Holdings, Inc. entered into Purchase Agreement with KENE Holdings, L.P. and KENE Parent, Inc. ("Entrust") valued at $2,400,000,000 (effective 2026-01-23).
“On January 23, 2026, Leidos, Inc. (the “ Purchaser ”), a Delaware corporation and wholly-owned subsidiary of Leidos Holdings, Inc. (“ Leidos ”), entered into a Stock Purchase Agreement (the “ Purchase Agreement ”) with KENE Holdings, L.P., a Delaware limited partnership (the “ Seller ”) and KENE Parent, Inc., a Delaware corporation (“ Entrust ”).”
Ascent Solar Technologies, Inc. entered into Registration Rights Agreement with certain institutional and accredited investors (effective 2026-01-23).
“In connection with the Private Placement, the Company entered into a registration rights agreement (the “Registration Rights Agreement”), dated as of January 23, 2026, with the Investors”
Ascent Solar Technologies, Inc. entered into Purchase Agreement with certain institutional and accredited investors valued at approximately $9.2 million (effective 2026-01-23).
“On January 23, 2026, Ascent Solar Technologies, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional and accredited investors (the “Investors”)”
Super Micro Computer, Inc. entered into Credit Agreement with various financial institutions from time to time party thereto as lenders, CTBC Bank Co., Ltd., Credit Agricole Corporate and Investment Bank, Taipei Branch and E.Sun Commercial Bank, Ltd. as mandated lead arrangers and bookrunners, and CTBC Bank Co., Ltd. as administrative agent valued at $350,000,000 ("Facility A1") and $360,000,000 ("Facility A2") (effective 2026-01-21).
“On January 21, 2026, Super Micro Computer, Inc. Taiwan (the “Borrower”), a wholly-owned subsidiary of Super Micro Computer, Inc. (the “Company”), entered into a facilities agreement (the “Credit Agreement”) by and among the Borrower, as the borrower, the various financial institutions from time to time party thereto as lenders, CTBC Bank Co., Ltd., Credit Agricole Corporate and Investment Bank, Taipei Branch and E.Sun Commercial Bank, Ltd. as mandated lead arrangers and bookrunners, and CTBC Bank Co., Ltd. as administrative agent (the “Administrative Agent”).”
ENERGY FUELS INC entered into Scheme Implementation Deed with Australian Strategic Materials Limited valued at approximately A$447 million (effective 2026-01-20).
“On January 20, 2026 (January 21, 2026 AWST), Energy Fuels Inc. (" Energy Fuels ") and Australian Strategic Materials Limited (" ASM ") entered into a Scheme Implementation Deed (the " Deed ")”
Orgenesis Inc. entered into Convertible Loan Agreement with Alpha Prosperity Fund SPC, acting on behalf of and for the account of Segregated Portfolio P valued at $1,000,000 convertible loan, a $10,000,000 credit facility (effective 2025-09-10).
“Orgenesis Inc. (the “Company”) entered into that certain Convertible Loan Agreement, dated September 10, 2025, by and among Theracell Laboratories IKE, the Company and Alpha Prosperity Fund SPC, acting on behalf of and for the account of Segregated Portfolio P (the “Lender”) with respect to a $1,000,000 convertible loan, a $10,000,000 credit facility”
AmpliTech Group, Inc. entered into Placement Agency Agreement with Moody Capital Solutions, Inc. valued at 6.0% of the aggregate gross proceeds (effective 2026-01-26).
“On January 26, 2026, the Company entered into a placement agency agreement with Moody Capital Solutions, Inc. (the “Placement Agent”) (the “Placement Agency Agreement”), pursuant to which the Company agreed to pay the Placement Agent an aggregate fee equal to 6.0% of the aggregate gross proceeds received by the Company from the sale of the Securities”
AmpliTech Group, Inc. entered into Securities Purchase Agreement with five institutional investors valued at $9,042,650 (effective 2026-01-26).
“On January 26, 2026, AmpliTech Group, Inc., a Nevada corporation (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with five institutional investors (the “Purchasers”) pursuant to which the Company agreed to sell in a registered direct offering (the “Offering”) 2,230,00 Units (“Units”) at $4.055 per Unit”
SPLASH BEVERAGE GROUP, INC. entered into Letter Agreement with C/M Capital Master Fund, LP valued at $525,000 (effective 2026-01-26).
“On January 26, 2026, Splash Beverage Group, Inc., a Nevada corporation (the “Company”) entered into an agreement (the “Letter Agreement”) with C/M Capital Master Fund, LP (the “Investor”) which Investor is the counterparty to that certain Securities Purchase Agreement dated September 19, 2025 establishing an equity line of credit facility between the Company and the Investor (the “ELOC Agreement”).”
Goldman Sachs BDC, Inc. entered into Underwriting Agreement with Goldman Sachs Asset Management, L.P. and SMBC Nikko Securities America, Inc., as representative of the several underwriters valued at $400,000,000 (effective 2026-01-21).
“On January 21, 2026, Goldman Sachs BDC, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) by and among the Company, Goldman Sachs Asset Management, L.P. and SMBC Nikko Securities America, Inc., as representative of the several underwriters named in Schedule A thereto (collectively, the “Underwriters”), in connection with the issuance and sale of $ 400,000,000 aggregate principal amount of the Company’s 5.100% notes due 2029 (the “Offering”).”
SKYX Platforms Corp. entered into Placement Agency Agreement with Roth Capital Partners, LLC (effective 2026-01-23).
“Roth Capital Partners, LLC acted as the exclusive placement agent (the “Placement Agent”) on a best efforts basis in connection with the Offering pursuant to that certain placement agency agreement, dated January 23, 2026 (the “Placement Agency Agreement”), by and between the Company and the Placement Agent. Pursuant to the Placement Agency Agreement, the Placement Agent will receive a cash fee of 6.5% of the aggregate gross proceeds paid to the Company for the securities sold in the Offering and reimbursement of certain out-of-pocket expenses of $75,000.”
SKYX Platforms Corp. entered into Purchase Agreement with an institutional investor valued at approximately $25.0 million (effective 2026-01-23).
“On January 23, 2026, SKYX Platforms Corp. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional investor, pursuant to which the Company agreed to issue to the purchaser in a registered direct offering (the “Offering”) 10,000,000 shares of the Company’s common stock, no par value per share (the “Common Stock”), at an offering price of $2.50 per share. The aggregate gross proceeds to the Company from the Offering will be approximately $25.0 million, before deducting placement agent fees and other estimated offering expenses.”
Stoke Therapeutics, Inc. entered into Lease Agreement with NWALP PHOP Property Owner LLC valued at approximately 98,500 square feet (effective 2026-01-21).
“On January 21, 2026, Stoke Therapeutics, Inc. (the “Company”) entered into a new lease for its corporate headquarters and laboratory with NWALP PHOP Property Owner LLC, located at 245 Fifth Avenue, Waltham, Massachusetts (the “Lease Agreement”), in order to expand its office and laboratory space.”
Indivior Pharmaceuticals, Inc. amended First Amendment to Note Purchase Agreement with RBP Global Holdings Limited, Piper Sandler Finance LLC, as Administrative Agent and the lenders from time to time party thereto (effective 2026-01-26).
“Amendment to Note Purchase Agreement Effective January 26, 2026, following the effectiveness of the U.S. Domestication, RBP Global Holdings Limited, Piper Sandler Finance LLC, as Administrative Agent and the lenders from time to time party thereto entered into that certain First Amendment to Note Purchase Agreement with respect to the Note Purchase Agreement, dated as of November 4, 2024 (the “Note Purchase Agreement”)”
Cardlytics, Inc. entered into Purchase Agreement with PAR Technology Corporation and DB Sub, LLC valued at $27,500,000 (effective 2026-01-23).
“On January 23, 2026 (the “Signing Date”), Cardlytics, Inc. (the “Company”), PAR Technology Corporation (“PAR”) and DB Sub, LLC, an indirectly wholly owned subsidiary of PAR (“Buyer”), entered into an asset purchase agreement (the “Purchase Agreement”), pursuant to which Buyer agreed to acquire all of the Company’s assets, properties and rights primarily related to, or primarily used in, its Bridg platform (the “Purchased Assets” and the sale by the Company thereof, the “Bridg Sale”), subject to certain exceptions.”
Autolus Therapeutics plc entered into Master Service Agreement with AGC Biologics S.p.A. valued at EUR 25 million (effective 2026-01-21).
“On January 21, 2026, Autolus Limited, a wholly owned subsidiary of Autolus Therapeutics plc (the “ registrant ”, and together with Autolus Limited, the “ Company ”), entered into a Master Service Agreement with AGC Biologics S.p.A (“ AGC ”) for the manufacture and supply of lentiviral vector (the “ Agreement ”)”
Aptera Motors Corp entered into Placement Agency Agreement with A.G.P./Alliance Global Partners (effective 2026-01-22).
“the Company entered into a placement agency agreement (the “ Placement Agency Agreement ”), dated January 22, 2026, with A.G.P./Alliance Global Partners (the “ Placement Agent ”) pursuant to which the Company agreed to pay the Placement Agent a total cash fee equal to 7.0% of the aggregate gross proceeds of the Offering and to reimburse the Placement Agent for (i) up to $10,000 for non-accountable expenses and (ii) up to $75,000 for the out-of-pocket accountable legal expenses incurred by the Placement Agent in connection with the Offering.”
Aptera Motors Corp entered into Purchase Agreement with certain investors valued at $9,000,000 (effective 2026-01-22).
“Certain of the investors purchased their Shares and Common Warrants pursuant to a securities purchase agreement dated January 22, 2026 by and among the Company and such investors (the “ Purchase Agreement ”).”
Limitless X Holdings Inc. entered into CFI Note with CFI Capital, LLC valued at $150,000.00 (effective 2025-11-03).
“On November 3, 2025, the Company entered into a Securities Purchase Agreement (the “CFI SPA”) with CFI Capital, LLC (“CFI”), pursuant to which the Company agreed to issue and sell, and CFI agreed to purchase, a six percent (6%) convertible redeemable note (the “CFI Note”) in the aggregate principal amount of $150,000.00.”
Limitless X Holdings Inc. entered into Lease with RWBP Highland, L.P. valued at $14,306.25 per month (effective 2025-10-15).
“On October 15, 2025, Limitless Entertainment, Inc. (“Limitless Entertainment”), a wholly-owned subsidiary of the Limitless X Holdings Inc. (the “Company”) entered into Retail Lease with RWBP Highland, L.P. (“Landlord”) for the premises located at 1724 N Highland Avenue Suite 270, Los Angeles, California 9002”
NEXTNRG, INC. entered into Stock Purchase Agreement with an investor valued at $500,000 (effective 2026-01-20).
“(the “Company”) entered into a Stock Purchase Agreement (the “SPA”) with an investor (the “Purchaser”). Pursuant to the terms of the SPA, the Company agreed to sell, and the Purchaser”
SkyWater Technology, Inc entered into Agreement and Plan of Merger with IonQ, Inc. (effective 2026-01-25).
“On January 25, 2026, SkyWater Technology, Inc., a Delaware corporation (the “Company” or “SkyWater”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with IonQ, Inc., a Delaware corporation (“Parent” or “IonQ”), Iris Merger Subsidiary 1 Inc., a Delaware corporation and a wholly owned subsidiary of IonQ (“Merger Sub 1”), and Iris Merger Subsidiary 2 LLC, a Delaware limited liability company and a wholly owned subsidiary of Parent (“Merger Sub 2””
IonQ, Inc. entered into Agreement and Plan of Merger with SkyWater Technology, Inc., Iris Merger Subsidiary 1 Inc., and Iris Merger Subsidiary 2 LLC (effective 2026-01-25).
“On January 25, 2026, IonQ, Inc., a Delaware corporation (the “ Company ”), SkyWater Technology, Inc., a Delaware corporation (“ SkyWater ”), Iris Merger Subsidiary 1 Inc., a Delaware corporation (“ Merger Sub 1 ”), and Iris Merger Subsidiary 2 LLC, a Delaware limited liability company (“ Merger Sub 2 ” and, together with Merger Sub 1, the “ Merger Subs ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”)”
NKGen Biotech, Inc. amended Alpine Second Amendment with AlpineBrook Capital GP I Limited valued at $372,000 (effective 2026-01-23).
“On January 23, 2026, the Company and NKGen Operating Biotech, Inc., a Delaware corporation (together with the Company, the “Borrowers”), entered into a second amendment (the “Alpine Second Amendment”) to that certain secured promissory note with AlpineBrook Capital GP I Limited, dated January 5, 2026, as amended by that certain amendment to secured promissory note dated January 12, 2026 (the “Note”). The Alpine Second Amendment provides an additional $372,000 of funding to the Borrowers (the “Third Additional New Loan”). As a result, the principal amount of the Note was increased to $26,507,106.”
NKGen Biotech, Inc. amended FPA Amendment with Seller (Meteora Strategic Capital, LLC, Meteora Capital Partners, LP, and Meteora Select Trading Opportunities Master, LP) (effective 2026-01-20).
“On January 20, 2026, NKGen Biotech, Inc. (the “Company” and formerly known as Graf Acquisition Corp. IV) and Seller (defined below) entered into an eighth amendment (the “FPA Amendment”) to the forward purchase agreement, dated as of September 22, 2023 (the “FPA”), initially among the Company, Graf, Meteora Strategic Capital, LLC (“MSC”), Meteora Capital Partners, LP (“MCP”) and Meteora Select Trading Opportunities Master, LP (“MSTO” with MSC, MCP, and MSTO collectively, “Seller”) for OTC Equity Prepaid Forward Transactions, as amended on December 26, 2023, as further amended on January 2, 2024, January 11, 2024, February 21, 2024, July 12, 2024, September 5, 2024, and December 31, 2024.”
DevvStream Corp. entered into Term Sheet with XCF Global, Inc., Southern Energy Renewables, Inc., and EEME Energy SPV I LLC (effective 2026-01-26).
“On January 26, 2026, DevvStream Corp., an Alberta corporation (the “Company”) entered into a binding term sheet (the “Term Sheet”) with XCF Global, Inc., a Delaware corporation (“XCF”), Southern Energy Renewables, Inc., a Louisiana corporation (“Southern”), and EEME Energy SPV I LLC (“EEME”), which sets forth the principal terms and conditions of a proposed business combination and related financing transactions (collectively, the “Proposed Transaction”).”
Orion Properties Inc. entered into Cooperation Agreement with The Kawa Fund Limited and Kawa Capital Management, Inc. (collectively, Kawa) (effective 2026-01-26).
“On January 26, 2026, Orion Properties Inc. (the “ Company ”) entered into a cooperation agreement (the “ Cooperation Agreement ”) with The Kawa Fund Limited and Kawa Capital Management, Inc. (collectively, “ Kawa ”)”
Keen Vision Acquisition Corp. amended Trust Amendment with Continental Stock Transfer & Trust Company (effective 2026-01-22).
“Keen Vision Acquisition Corporation (“ KVAC ”) entered into an amendment to the Investment Management Trust Agreement, with Continental Stock Transfer & Trust Company (the “ Trust Amendment ”) dated as of January 22, 2026.”
XCF Global, Inc. entered into Term Sheet with Southern Energy Renewables, Inc., DevvStream Corp., and EEME Energy SPV I LLC valued at $10 million (effective 2026-01-26).
“On January 26, 2026, XCF Global, Inc., a Delaware corporation (“ XCF ” or the “ Company ”), entered into a binding term sheet (the “ Term Sheet ”) with Southern Energy Renewables, Inc., a Louisiana corporation (“ Southern ”), DevvStream Corp., an Alberta corporation (“ DEVS ”), and EEME Energy SPV I LLC (“ EEME ”), which sets forth the principal terms and conditions of a proposed business combination and related financing transactions”
VisionWave Holdings, Inc. entered into Exchange Agreement with SaverOne 2014 Ltd. valued at up to $7.0 million (effective 2026-01-26).
“On January 26, 2026, VisionWave Holdings, Inc. (the “Company” or “VisionWave”) entered into a definitive Exchange Agreement (the “Exchange Agreement”) with SaverOne 2014 Ltd.”
WhiteFiber, Inc. entered into Indenture with U.S. Bank Trust Company, National Association valued at $230.0 million aggregate principal amount of 4.500% Convertible Senior Notes due 2031 (effective 2026-01-26).
“On January 26, 2026, WhiteFiber, Inc. (the “ Company ”) completed its previously announced private offering (the “ Offering ”) of $230.0 million aggregate principal amount of its 4.500% Convertible Senior Notes due 2031 (the “ Notes ”), including the exercise in full of the initial purchasers’ option to purchase an additional $20.0 million aggregate principal amount of Notes.”
Mount Logan Capital Inc. entered into Indenture with U.S. Bank Trust Company, National Association valued at $40.0 million (effective 2026-01-26).
“On January 26, 2026, in connection with a previously announced public offering, Mount Logan Capital Inc. (the “Company”) and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), entered into an Indenture (the “Base Indenture”) and a First Supplemental Indenture (the “First Supplemental Indenture” and, together with the Base Indenture, the “Indenture”).”
Lionsgate Studios Corp. entered into Governance, Standstill and Voting Agreement with Liberty 77 Capital L.P., Liberty 77 Fund L.P., Liberty 77 Fund International L.P., and MHR Fund Management, LLC and affiliated funds (effective 2026-01-26).
“On January 26, 2026, Lionsgate Studios Corp. (the “Company”) entered into a Governance, Standstill and Voting Agreement (the “Standstill Agreement”) with Liberty 77 Capital L.P., a Delaware limited partnership, Liberty 77 Fund L.P., a Cayman Islands exempted limited partnership, and Liberty 77 Fund International L.P., a Cayman Islands exempted limited partnership (each, a “Liberty Party,” and together, the “Liberty Parties”), and MHR Fund Management, LLC and affiliated funds (together, “MHR Fund Management”).”
DAXOR CORP entered into placement agency agreement with Lake Street Capital Markets, LLC (effective 2026-01-23).
“lacement agency agreement with Lake Street. A copy of the form of securities purchase agreement and the placement agency agreement are filed herewith as Exhibits 10.1 and 10.2, respectively,”
DAXOR CORP entered into securities purchase agreement with certain investors valued at $11.75 per share (effective 2026-01-23).
“On January 23, 2026, Daxor Corporation (“we” or “us”) entered into a definitive securities purchase agreement with certain investors pursuant to which we issued and sold an aggregate of 765,958 registered shares of our common stock at $11.75 per share”
GRAHAM CORP entered into Second Amendment with Wells Fargo Bank National Association valued at Revolving credit limit increased from $50.0 million to $80.0 million; permits up to $5.0 million in (effective 2026-01-23).
“On January 23, 2026, Graham Corporation (the “Company”) entered into a second amendment (the “Second Amendment”) to its existing credit agreement, by and between the Company and Wells Fargo Bank National Association (“Wells Fargo”), dated as of October 13, 2023, as amended (the “Credit Agreement”).”
PAYCHEX INC terminated 2020 Credit Facility with PNC Bank, N.A. (as administrative agent) (effective 2026-01-23).
“Paychex Advance, LLC, a New York limited liability company (“Paychex Advance”) and the Parent terminated, effective January 23, 2026, the three-year, $250 million, unsecured, revolving credit facility established in favor of Paychex Advance as borrower on February 6, 2020 ( as previously amended and extended from time to time, the “2020 Credit Facility”) and for which PNC Bank, N.A. acted as administrative agent.”
PAYCHEX INC amended 2019 Credit Facility Amendment with JPMorgan Chase Bank, N.A. (as Administrative Agent) (effective 2026-01-23).
“On January 23, 2026, PoNY and the Parent, entered into an amendment (the “2019 Credit Facility Amendment”) to the $1.0 billion, five-year, unsecured, revolving credit facility established in favor of PoNY as borrower on July 31, 2019”
PAYCHEX INC amended 2017 Credit Facility Amendment with JPMorgan Chase Bank, N.A. (as Administrative Agent) (effective 2026-01-23).
“On January 23, 2026, Paychex of New York LLC, a Delaware limited liability company (“PoNY”) and Paychex, Inc., a Delaware corporation (the “Parent”) entered into an amendment (the “2017 Credit Facility Amendment”) to the $750.0 million, five-year, unsecured, revolving credit facility established in favor of PoNY as borrower on August 17, 2017”
VIASAT INC entered into Ex-Im Credit Facility with Export-Import Bank of the United States valued at $188.7 million (effective 2026-01-21).
“On January 21, 2026, Viasat, Inc. (“Viasat”) and ViaSat Technologies Limited, a company organized under the laws of England and a wholly owned subsidiary of Viasat (“VTL”), entered into a Credit Agreement (the “Ex-Im Credit Facility”) by and among VTL, as borrower, Viasat, as guarantor, J.P. Morgan Securities LLC, as Ex-Im Facility Agent, and the Export-Import Bank of the United States (“Ex-Im Bank”).”
LANDS' END, INC. entered into Membership Interest Purchase Agreement with WHP Borrower, LLC; WHP Topco, L.P. (d/b/a WHP Global); LEWHP LLC valued at $300 million in cash (effective 2026-01-26).
“On January 26, 2026, Lands’ End, Inc., a Delaware corporation (the “ Company ”), entered into a Membership Interest Purchase Agreement (the “ MIPA ”)”
AETHLON MEDICAL INC amended Amendment to Pre-Funded Common Stock Purchase Warrant with institutional investor valued at Amendment removed requirement that Company obtain shareholder approval for exercise of pre-funded wa (effective 2026-01-22).
“Also on January 22, 2026, the Company and the Purchaser entered into the Amendment to Pre-Funded Common Stock Purchase Warrant (the “PFW Amendment”). The PFW Amendment amends the terms of that certain Pre-Funded Common Stock Purchase Warrant by and between the Company and the Purchaser dated December 8, 2025 (the “Warrant”), as previously disclosed on the Current Report on Form 8-K filed by the Company on December 8, 2025. The PFW Amendment removed the requirement that Company obtain shareholder approval of issuance or exercise the pre-funded warrants under Nasdaq 5635 prior to those pre-funded warrants becoming exercisable. As a result, the pre-funded warrants are immediately exercisable.”
AETHLON MEDICAL INC amended Amendment to Securities Purchase Agreement with institutional investor valued at Amendment removed requirement that Company obtain shareholder approval for exercise of pre-funded wa (effective 2026-01-22).
“On January 22, 2026, Aethlon Medical, Inc. (the “Company”) and an institutional investor (the “Purchaser”) entered into the Amendment to Securities Purchase Agreement (the “SPA Amendment”). The SPA Amendment amends the terms of that certain Securities Purchase Agreement by and between the Company and the Purchaser dated December 5, 2025 (the “Securities Purchase Agreement”), as previously disclosed on the Current Report on Form 8-K filed by the Company on December 8, 2025. The SPA Amendment removed the requirement that Company obtain shareholder approval of issuance or exercise the pre-funded warrants under Nasdaq 5635 prior to those pre-funded warrants becoming exercisable. As a result, the pre-funded warrants are immediately exercisable. All other terms of the Securities Purchase Agreement remain unchanged.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.